JPH0239882A - Culture medium for animal cell - Google Patents
Culture medium for animal cellInfo
- Publication number
- JPH0239882A JPH0239882A JP63187984A JP18798488A JPH0239882A JP H0239882 A JPH0239882 A JP H0239882A JP 63187984 A JP63187984 A JP 63187984A JP 18798488 A JP18798488 A JP 18798488A JP H0239882 A JPH0239882 A JP H0239882A
- Authority
- JP
- Japan
- Prior art keywords
- medium
- animal cell
- organ
- extract
- acetone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004102 animal cell Anatomy 0.000 title claims abstract description 33
- 239000001963 growth medium Substances 0.000 title abstract description 6
- 210000004185 liver Anatomy 0.000 claims abstract description 11
- 239000006143 cell culture medium Substances 0.000 claims description 15
- 102000004895 Lipoproteins Human genes 0.000 claims description 13
- 108090001030 Lipoproteins Proteins 0.000 claims description 13
- 210000003734 kidney Anatomy 0.000 claims description 11
- 210000002969 egg yolk Anatomy 0.000 claims description 6
- 235000013345 egg yolk Nutrition 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 72
- 239000007640 basal medium Substances 0.000 abstract description 28
- 239000000843 powder Substances 0.000 abstract description 24
- 239000002609 medium Substances 0.000 abstract description 21
- 210000000056 organ Anatomy 0.000 abstract description 19
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 239000007788 liquid Substances 0.000 abstract description 13
- 241000283690 Bos taurus Species 0.000 abstract description 7
- 241000251468 Actinopterygii Species 0.000 abstract description 2
- 241000283073 Equus caballus Species 0.000 abstract description 2
- 244000144977 poultry Species 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 7
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960001471 sodium selenite Drugs 0.000 description 4
- 235000015921 sodium selenite Nutrition 0.000 description 4
- 239000011781 sodium selenite Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は動物細胞培養用培地、特にモノクローナル抗体
を産生ずるハイブリドーマなどの動物細胞を増殖させる
ために有用な動物細胞培養用培地に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to an animal cell culture medium, particularly to an animal cell culture medium useful for propagating animal cells such as hybridomas that produce monoclonal antibodies. .
一般に動物細胞培養用培地は、基本的に、ビタミン類、
無機塩類、アミノ酸などを含有してなる基礎培地に各種
の添加物が添加されて成るものである。そして、基礎培
地については種々の組成のものが市販されているので、
培養すべき動物細胞の種類に応じて所望のものを容易に
入手することができるが、これに添加すべき添加物の種
類や量については不明瞭な部分が多いのが現状である。In general, animal cell culture media basically contain vitamins,
It is made by adding various additives to a basal medium containing inorganic salts, amino acids, etc. As for the basal medium, various compositions are commercially available, so
Although desired products can be easily obtained depending on the type of animal cells to be cultured, there are currently many uncertainties regarding the types and amounts of additives that should be added thereto.
従って、ある増殖因子の性能の評価においては、評価す
る者の個人差、培養対象である動物細胞の種類や培養条
件などによって結果が大きく変動することとなる。Therefore, when evaluating the performance of a certain growth factor, the results will vary greatly depending on the individual differences of the evaluator, the type of animal cells to be cultured, the culture conditions, etc.
斯かる状況において、比較的安定な結果が得られる添加
物として牛胎児血清が知られている(文献「細胞培養マ
ニュアル」、講談社すイエンティフィク社刊、1982
)。そして同じ牛由来の血清であっても、成牛や子牛由
来のものは動物細胞の増殖を阻害する物質を含んでいる
とされ、一般に牛胎児血清と同様な細胞増殖能を期待す
ることはできない。Under such circumstances, fetal bovine serum is known as an additive that provides relatively stable results (Reference ``Cell Culture Manual'', published by Kodansha Scientific, 1982).
). Even if serum is derived from the same cow, those derived from adult cows and calves are said to contain substances that inhibit the proliferation of animal cells, so it is generally not expected to have the same cell proliferation ability as fetal bovine serum. Can not.
しかしながら、牛胎児血清を添加した培地は、当該牛胎
児血清の供給が安定でないため、動物細胞を工業的規模
で培養する場合の培地として好ましいものではない。However, a medium to which fetal bovine serum is added is not preferred as a medium for culturing animal cells on an industrial scale because the supply of the fetal bovine serum is not stable.
また、牛胎児血清は基礎培地に対して通常5〜15%も
の大きな割合で添加する必要があるが、その結果、牛胎
児血清に由来するタンパク質が基礎培地に多量に含まれ
ることとなり、例えば、牛胎児血清を基礎培地に10容
量%添加した場合にはタンパク質濃度は3000〜40
00μgZmlもの高濃度となり、そのため、動物細胞
から培地中に産生される有用物質の分離および精製が非
常に困難になっていた。しかし、牛胎児血清の添加量を
減少させることは、細胞の増殖速度が低下するので、有
利なことではない。In addition, fetal bovine serum usually needs to be added at a large ratio of 5 to 15% to the basal medium, but as a result, a large amount of protein derived from fetal bovine serum is contained in the basal medium. When fetal bovine serum was added to the basal medium at 10% by volume, the protein concentration was 3000-40%.
The concentration was as high as 00 μgZml, making it extremely difficult to separate and purify useful substances produced in the culture medium from animal cells. However, reducing the amount of fetal bovine serum added is not advantageous since the rate of cell proliferation decreases.
本発明は、上記のような現状から、含有タンパク質量が
低く、安価でかつ安定的な供給を確保することができ、
しかも性能の安定した動物細胞培養用培地を提供するこ
とを目的とする。In light of the above-mentioned current situation, the present invention can ensure a stable supply of protein containing low amounts and at low cost.
Moreover, it is an object of the present invention to provide an animal cell culture medium with stable performance.
本発明の動物細胞培養用培地は、肝臓および/または胃
臓由来の抽出成分を含有することを特徴とする。The animal cell culture medium of the present invention is characterized by containing extracted components derived from liver and/or stomach organs.
以下、本発明について具体的に説明する。The present invention will be specifically explained below.
本発明においては、基礎培地に、肝臓および/または胃
臓由来の抽出成分を添加して含有させることにより、動
物細胞培養用培地を得る。In the present invention, a medium for animal cell culture is obtained by adding and containing extracted components derived from liver and/or stomach organs to a basal medium.
本発明において、基礎培地としては、培養すべき動物細
胞の種類に応じて選択される市販の培地を使用すること
ができる。その具体例としては、例えばr RPMI
1640 J、「ハムF12」、「ダルベツコ改変イー
グルメディウムJ (DMEM)、rミニマルエッセン
シャルメディムJ (MEM)などを挙げることができ
るが、これらのうち、浮遊系細胞培養用として開発され
たRPMl 1640を特に好適に使用することができ
る。また、これらの培地は適宜混合して使用することも
できる。In the present invention, a commercially available medium selected depending on the type of animal cells to be cultured can be used as the basal medium. As a specific example, for example, r RPMI
1640 J, "Ham F12", "Dulbetzko Modified Eagle Medium J (DMEM)", rMinimal Essential Medium J (MEM), etc. Among these, RPMl 1640, which was developed for suspension cell culture. These media can be used particularly preferably.Furthermore, these media can also be used as a mixture as appropriate.
本発明において含有される抽出成分は、肝臓および/ま
たは腎II!(以下「特定の臓器」という)由来のもの
である。この抽出成分を得るための特定の臓器は、牛、
豚、馬、鳥、魚などのものを用いることができるが、入
手が容易な点で特に牛または豚のものが好ましい。The extracted components contained in the present invention include liver and/or kidney II! (hereinafter referred to as "specific organs"). The specific organs for obtaining this extracted ingredient are cow,
Pork, horse, poultry, fish, etc. can be used, but cow or pork is particularly preferred because they are easily available.
本発明において抽出成分は、新鮮な特定の臓器から、水
、リン酸緩衝液、0.15M程度の塩化ナトリウム水溶
液などを用いて直接抽出液として調製することもできる
が、特定の臓器を一旦アセトン粉末となし、使用時にこ
のアセトン粉末から特定の臓器由来の抽出液(以下、単
に「抽出液」という)を調製する方法が、抽出成分の工
業的な大量処理が可能となると共に保存も容易となるこ
とから好ましい。In the present invention, the extract component can be prepared as an extract directly from a fresh specific organ using water, phosphate buffer, about 0.15M sodium chloride aqueous solution, etc.; A method of preparing extracts derived from specific organs (hereinafter simply referred to as "extracts") from this acetone powder at the time of use enables industrial large-scale processing of extracted components and facilitates storage. It is preferable because
特定の臓器の抽出成分をアセトン粉末とする場合におい
て、その調製法は特に限定されるものではないが、その
−例を示すと次のとおりである。In the case where the extract component of a specific organ is made into acetone powder, the preparation method thereof is not particularly limited, but an example thereof is as follows.
まず新鮮な特定の臓器から結合組織を除去して十分に放
血させ、次いで凍結させ、この凍結臓器を粗く砕いたも
のを、5〜20倍量の一20〜10℃程度のアセトン(
以下、「冷アセトン」という)および5〜10倍量のO
〜20℃程度の冷水と共にブレンダーに投入し、数分間
ホモジナイズして摩砕物を得、更にこの摩砕物を濾過し
て固形物を得、この固形物を冷アセトンおよび一20〜
10℃程度のエーテル(以下、「冷エーテル」という)
で十分に洗浄し、その後低温条件下で乾燥させ、必要に
応じて繊維状物をふるい分けにより除去して、目的とす
る特定の臓器のアセトン粉末を得る。このアセトン粉末
は、例えば5℃以下の冷暗所に長期間にわたって保存す
ることが可能である。First, connective tissue is removed from a fresh specific organ and blood is thoroughly exsanguinated, then frozen, and the frozen organ is coarsely crushed and mixed with 5 to 20 times the amount of acetone (about 20 to 10 degrees Celsius).
(hereinafter referred to as "cold acetone") and 5 to 10 times the amount of O
The mixture was poured into a blender with cold water at ~20°C, homogenized for several minutes to obtain a ground product, and the ground product was further filtered to obtain a solid.
Ether at about 10℃ (hereinafter referred to as "cold ether")
The sample is thoroughly washed with water, then dried under low temperature conditions, and if necessary, fibrous materials are removed by sieving to obtain acetone powder of the desired specific organ. This acetone powder can be stored, for example, in a cool, dark place at 5° C. or lower for a long period of time.
以上のように、アセトン粉末の調製は、冷アセトンおよ
び冷エーテルを用いて行うことができる(参考文献:新
実験化学講座20.生物工学I 2゜6〜7)が、他の
有機溶剤を併用して行うこともできる(参考文献: R
obert L、 Hill et al、。As mentioned above, acetone powder can be prepared using cold acetone and cold ether (Reference: New Experimental Chemistry Course 20. Biotechnology I 2゜6-7), but other organic solvents can also be used in combination. (Reference: R
Obert L, Hill et al.
Biochemical Preparation
s、 pJ5. 1954>。 その具体的−例
を示すと次のとおりである。例えば凍結状態にある特定
の臓器をグラインダーで粉砕したもの300gに対して
100〜200顎の水と共にブレンダーに投入し、2〜
6℃程度で数分間攪拌した上50容量%程度のエタノー
ル水溶液30〜100m1を加えて2〜6℃程度に保っ
たまま数時間静置し、次いで10〜31]tl!のクロ
ロホルムを含有する95容量%程度のエタノール水溶液
100〜200 rnlを加える。モして濾別により固
形物を分離し、これに2〜6℃のアセトン300〜60
0 m!!を加え、更に数時間静置して固形物を回収し
、これを再度冷アセトン300〜600 dに懸濁させ
、再び濾別により固形物を回収し、これを、50〜15
0 mNのアセトン、30〜100−の冷アセトンと冷
エーテルとの等1混合物および30〜100m1の冷エ
ーテルによって順次洗浄し、その後洗浄液を十分に除去
して減圧乾燥し、目的とするアセトン粉末を得る。Biochemical Preparation
s, pJ5. 1954>. Specific examples are as follows. For example, grind 300g of a specific organ in a frozen state with a grinder, add 100 to 200 jaws of water to a blender, and
After stirring for several minutes at about 6°C, 30 to 100 ml of an aqueous ethanol solution of about 50% by volume was added and left to stand for several hours while maintaining the temperature at about 2 to 6°C, and then 10 to 31]tl! Add 100 to 200 rnl of an approximately 95% by volume aqueous ethanol solution containing chloroform. The solid matter was separated by filtration, and this was added with 300 to 60 ml of acetone at 2 to 6°C.
0 m! ! was added and left to stand for several hours to recover the solid matter, which was again suspended in 300 to 600 d of cold acetone, and the solid matter was recovered by filtration again.
Wash sequentially with 0 mN of acetone, a mixture of 30 to 100 mN of cold acetone and cold ether, and 30 to 100 m of cold ether, then thoroughly remove the washing liquid and dry under reduced pressure to obtain the desired acetone powder. obtain.
また、特定の臓器のアセトン粉末は市販されており、こ
れを使用することもできる。In addition, acetone powder for specific organs is commercially available and can also be used.
上記特定の臓器のアセトン粉末から、基礎培地に添加さ
れる抽出液を調製するための方法は、特に限定されるも
のではないが、その−例においては、アセトン粉末にそ
の50g当り約300〜600m1の0.15M程度の
塩化す) IJウム溶液やリン酸緩衝液などの生理的塩
類溶液あるいは使用される基礎培地と同一の液体を加え
、37℃で約10〜60分間撹拌し、得られる懸濁液を
例えば3000rpmで約10〜60分間遠心分離処理
して上澄み液を得、これを抽出液とする。この抽出液は
、フィルターで濾過して滅菌し、必要に応じてタンパク
質濃度を測定した上で例えば−20℃以下で凍結保存す
る。The method for preparing the extract to be added to the basal medium from the acetone powder of the above-mentioned specific organ is not particularly limited, but in one example, the acetone powder is mixed with about 300 to 600 ml per 50 g of the acetone powder. Add a physiological salt solution such as IJum solution or phosphate buffer, or the same liquid as the basal medium to be used, and stir at 37°C for about 10 to 60 minutes. The suspension is centrifuged at, for example, 3000 rpm for about 10 to 60 minutes to obtain a supernatant, which is used as an extract. This extract is sterilized by filtration, and if necessary, the protein concentration is measured and stored frozen at, for example, -20°C or lower.
以上のようにして得られる抽出液におけるタンパク質濃
度は、通常、1〜100■/−の範囲である。The protein concentration in the extract obtained as described above is usually in the range of 1 to 100 μ/-.
本発明においては、以上のようにして得られる抽出液を
、通常、基礎培地に対してタンパク質濃度が1〜100
■/dとなる割合で添加する。In the present invention, the extract obtained as described above is usually used at a protein concentration of 1 to 100% relative to the basal medium.
■ Add at a ratio of /d.
本発明においては、基礎培地に対し、上記抽出成分と共
に、その細胞増殖能をさらに発揮させるために種々の物
質を添加してもよい。その具体例としては、基礎培地中
での濃度が1〜100μg/mfとなる割合のインスリ
ン、1〜100μg/ml!となる割合のトランスフェ
リン、2〜200μg/mlとなる割合のエタノールア
ミン、10−’〜10−9モル/!となる割合の2−メ
ルカプトエタノール、10−7〜10−9モル/flと
なる割合の亜セレン酸ナトリウム、1〜100μg/r
nlとなる割合のフェツインなどを挙げることができる
。In the present invention, various substances may be added to the basal medium together with the above extract components in order to further exhibit its cell proliferation ability. As a specific example, insulin at a rate such that the concentration in the basal medium is 1 to 100 μg/mf, 1 to 100 μg/ml! Transferrin in a proportion of 2 to 200 μg/ml, ethanolamine in a proportion of 10-' to 10-9 mol/! 2-mercaptoethanol in a proportion of 1 to 100 μg/r, sodium selenite in a proportion of 10-7 to 10-9 mol/fl
Examples include fetuin with a proportion of nl.
更に本発明の動物細胞培養用培地による培養においては
、当該培地に脂質を加えることがきわめて有効である。Furthermore, in culturing using the animal cell culture medium of the present invention, it is extremely effective to add lipids to the medium.
この脂質としては特に卵黄由来のリポタンパク質が好ま
しく、これを添加することにより、上記抽出液の細胞増
殖能を一層高くすることができる。リポタンパク質を得
るための卵黄は、特に制限されるものではないが、人手
の容易性、価格などの点から鶏卵の卵黄が好適に使用さ
れる。The lipid is particularly preferably lipoprotein derived from egg yolk, and by adding this, the cell proliferation ability of the above-mentioned extract can be further enhanced. The egg yolk used to obtain lipoproteins is not particularly limited, but chicken egg yolk is preferably used from the viewpoint of ease of use and cost.
卵黄からリポタンパク質を得るための代表的な方法は以
下のとおりである。100個の鶏卵の卵黄に対し、0.
1〜0.2Mの塩化ナトリウム溶液1.5〜3flを加
えて室温で10〜60分間程度撹拌し、これを約300
Orpmで5〜15分間程度遠心分離処理して上澄み液
を得、更に例えば17000 rpmで10〜60分間
程度遠心分離処理して上澄み液を得、これを蒸留水によ
って透析し更に濾過し滅菌してリポタンパク質溶液を得
る。このリポタンパク質溶液の基礎培地に対する添加量
はタンパク質濃度が20〜500μg/mfとなる割合
である。A typical method for obtaining lipoproteins from egg yolk is as follows. 0.0 for the yolk of 100 chicken eggs.
Add 1.5 to 3 fl of a 1 to 0.2 M sodium chloride solution and stir at room temperature for about 10 to 60 minutes.
Orpm for about 5 to 15 minutes to obtain a supernatant, further centrifuged at, for example, 17,000 rpm for about 10 to 60 minutes to obtain a supernatant, which is dialyzed with distilled water and further filtered and sterilized. Obtain a lipoprotein solution. The amount of this lipoprotein solution added to the basal medium is such that the protein concentration is 20 to 500 μg/mf.
さらに、本発明の動物細胞要用培地には、牛胎児血清を
添加してもよい。Furthermore, fetal bovine serum may be added to the animal cell culture medium of the present invention.
本発明の動物細胞培養用培地は、モノクローナル抗体の
産生細胞とミエローマの融合により得られるハイブリド
ーマ、浮遊系細胞であるリンパ系細胞、3alb/Cマ
ウスの膵臓細胞とN5−1細胞とのハイブリドーマ、黒
色種由来のBOWES細胞、ハイブリドーマの作製に用
いる親株であるミエローマ、例えばSP210−Ag−
14(以下rsP210細胞」という)、P3/NSl
−Ag4−1 (以下rNs−1細胞」という)などの
培養に好適に使用することができるが、これらに限定さ
れるものではなく、種々の動物細胞の培養に利用するこ
とができる。The animal cell culture medium of the present invention includes hybridomas obtained by fusion of monoclonal antibody-producing cells and myeloma, lymphoid cells that are floating cells, hybridomas of pancreatic cells of 3alb/C mice and N5-1 cells, and black Species-derived BOWES cells, myeloma that is the parent strain used for hybridoma production, e.g. SP210-Ag-
14 (hereinafter referred to as rsP210 cells), P3/NSl
-Ag4-1 (hereinafter referred to as rNs-1 cells), etc., but is not limited thereto, and can be used to culture various animal cells.
以下本発明の実施例について説明するが、本発明がこれ
らによって制限されるものではない。Examples of the present invention will be described below, but the present invention is not limited thereto.
実施例1
く豚腎臓アセトン粉末の調製〉
屠殺直後の豚の腎雀から結合組織を除去し、十分に放血
させた上当該臓器を凍結させて粗粉砕した。この臓器片
200gを、4℃に保った2000 gのアセトンと2
000 gの5℃の水と共にブレンダーに投入し、10
分間ホモジナイズして摩砕物を得、この摩砕物を濾過処
理して固形物を濾別した。この固形物を約4500 g
の冷アセトンで十分に洗浄し、更に約3000 gの冷
エーテルで洗浄し、5℃において送風機による乾燥を2
日間行って粉末を得、この粉末から繊維状物をふるい分
けにより除去して豚腎臓アセトン粉末を得た。この豚腎
臓アセトン粉末は、5℃の冷暗所に約6ケ月間以上保存
することが可能なものであった。Example 1 Preparation of Pig Kidney Acetone Powder Connective tissues were removed from pig kidneys immediately after slaughter, and the organ was thoroughly exsanguinated, frozen, and coarsely ground. 200g of this organ piece was mixed with 2000g of acetone kept at 4°C.
Pour into a blender with 000 g of 5℃ water and mix for 10
Homogenization was performed for a minute to obtain a ground product, which was then filtered to remove solid matter. Approximately 4500 g of this solid matter
Wash thoroughly with cold acetone, then with about 3000 g of cold ether, and dry with a blower at 5°C for 2 minutes.
Pig kidney acetone powder was obtained by removing fibrous substances from the powder by sieving. This pig kidney acetone powder could be stored in a cool, dark place at 5°C for about 6 months or more.
〈抽出液の調製〉
液体基礎培地RPM11640とハムF12とを体積比
で3;lの割合で混合して得られる混合液500mj!
を、上記の豚腎臓アセトン粉末100gに加えて37℃
で約30分間撹拌し、得られた懸濁液を300Orpm
で約30分間遠心分離処理して上澄み液を得、これを0
.22即のフィルターで濾過し滅菌して抽出液を調製し
た。この抽出液は各々容量50ffLl!のチニープに
充填して一20℃で凍結保存した。これを「抽出液■」
という。この抽出液■のタンパク質濃度をバイオランド
プロティンアッセイによる吸光光度法で測定したところ
、12mg/rnlであった。<Preparation of extract> 500 mj of a mixed liquid obtained by mixing liquid basal medium RPM11640 and Ham F12 at a volume ratio of 3:1!
Add to 100g of the above pig kidney acetone powder and heat at 37°C.
The resulting suspension was stirred at 300 rpm for about 30 minutes.
Centrifuge for about 30 minutes to obtain a supernatant, which is then
.. An extract was prepared by filtration and sterilization using a 22-day filter. Each of these extracts has a capacity of 50ffLl! The mixture was filled into tinips and stored frozen at -20°C. This is called “extract liquid■”
That's what it means. The protein concentration of this extract (2) was measured by spectrophotometry using Bioland protein assay and was found to be 12 mg/rnl.
く培地の調製〉
粉末基礎培地RPMT1640の30.6 gと、粉末
基礎培地ハムF12の10.6 gとを混合し、これを
超純水3.71に溶解させた。これにL−グルタミン酸
1.2gと、炭酸水素ナトリウム4.0gを添加して溶
解し、INの塩化ナトリウム水溶液によりpH7,3に
調整し、更に超純水を添加して全量を41とした後、濾
過し滅菌して基礎培地を得た。Preparation of medium> 30.6 g of powdered basal medium RPMT1640 and 10.6 g of powdered basal medium Ham F12 were mixed, and this was dissolved in 3.71 g of ultrapure water. To this, 1.2 g of L-glutamic acid and 4.0 g of sodium hydrogen carbonate were added and dissolved, the pH was adjusted to 7.3 with IN aqueous sodium chloride solution, and ultrapure water was added to bring the total amount to 41. , filtered and sterilized to obtain basal medium.
この基礎培地に、下記の物質を添加して動物細胞培養用
培地を調製した。The following substances were added to this basal medium to prepare a medium for animal cell culture.
抽出液■9,3ml
トランスフェリン 56 mgインス
リン 32 mgエタノールア
ミン 72 mg2−メルカプトエタ
ノール 4X10−@モル亜セレン酸ナトリウム
6X10−@モル実施例2
く豚肝臓アセトン粉末の調製〉
層殺直後の豚の新鮮な肝臓を実施例1と同様に凍結し、
粗粉砕した臓器片300gと、2500 gの冷アセト
ンと2300 gの5℃の水を用いた以外は実施例1と
同様の方法により、豚肝臓アセトン粉末を得た。Extract ■9.3ml Transferrin 56 mg Insulin 32 mg Ethanolamine 72 mg 2-mercaptoethanol 4X10-@mol Sodium selenite
6X10-@mol Example 2 Preparation of Pig Liver Acetone Powder> Fresh pig liver immediately after stratification was frozen in the same manner as in Example 1,
Pig liver acetone powder was obtained in the same manner as in Example 1, except that 300 g of coarsely crushed organ pieces, 2500 g of cold acetone, and 2300 g of 5°C water were used.
〈抽出液の調製〉
上記豚肝臓アセトン粉末120gにRPM11640培
地液800m1を加えて37℃で約40分間撹拌し、得
られた懸濁液を300Orpmで約30分間遠心分離処
理して上澄み液を得、これを0.22umフィルターで
濾過し滅菌して抽出液を調製した。これを「抽出液■」
という。この抽出液Hのタンパク質濃度を実施例1と同
様の方法で測定したところ、10.5■/xi!であっ
た。<Preparation of extract> Add 800 ml of RPM11640 medium to 120 g of the above pig liver acetone powder, stir at 37°C for about 40 minutes, and centrifuge the resulting suspension at 300 rpm for about 30 minutes to obtain a supernatant. This was filtered and sterilized using a 0.22 um filter to prepare an extract. This is called “extract liquid■”
That's what it means. When the protein concentration of this extract H was measured in the same manner as in Example 1, it was found to be 10.5/xi! Met.
くリポタンパク質の調製〉
新鮮な鶏卵200個から卵黄を取出し、0.16Mの塩
化す) +Jウム水溶液4βを加えて室温で40分間撹
拌し、この溶液を300Orpmで10分間遠心分離処
理して上澄み液を得、この上澄み液を更に17000r
pmで30分間遠心分離処理して3.ORの上澄み液を
得、これを蒸留水によって透析した後、2遮、0、80
JLQlおよび0.22u+nのフィルターでこの順に
濾過し滅菌してリポタンパク質溶液を調製し、これを小
バイアルに小分けして一20℃で保存した。これを「リ
ポタンパク質溶液A」という。このリポタンパク質溶液
へのタンパク質濃度を実施例1と同様の方法で測定した
ところ、19mg/−であった。Preparation of lipoprotein> Take the egg yolks from 200 fresh chicken eggs and dilute them with 0.16M chloride) Add Jum aqueous solution 4β, stir for 40 minutes at room temperature, and centrifuge this solution at 300 rpm for 10 minutes to remove the supernatant. This supernatant liquid was further heated for 17,000 r.
3. Centrifuge at pm for 30 minutes. After obtaining the OR supernatant and dialyzing it with distilled water,
A lipoprotein solution was prepared by filtration and sterilization in this order through JLQl and 0.22u+n filters, which was divided into small vials and stored at -20°C. This is called "lipoprotein solution A." The protein concentration in this lipoprotein solution was measured in the same manner as in Example 1 and was found to be 19 mg/-.
〈培地の調製〉
5、OAの液体基礎培地RPM11640に、以下の物
質を添加して動物細胞培養用培地を調製した。<Preparation of medium> 5. The following substances were added to OA's liquid basal medium RPM11640 to prepare a medium for animal cell culture.
抽出液II 9rnlリポタン
パク質溶液A 22 −トランスフェリン
85 ■インスリン
55 ■エタノールアミン 90
mg2−メルカプトエタノール 6X10−モル
亜セレン酸ナトリウム 5X10−モル実施例3
く牛腎臓アセトン粉末の調製〉
層殺直後の牛の”zmを実施例1と同様に処理し、粗粉
砕された臓器片350gと3300 gの冷アセトンと
3400 gの冷水とを用い、摩砕物を5200 gの
冷アセトンで洗浄した以外は実施例1と同様の方法によ
り牛賢臓アセトン粉末を得た。Extract II 9rnl lipoprotein solution A 22-transferrin
85 ■Insulin
55 ■Ethanolamine 90
mg2-Mercaptoethanol 6 x 10-mol Sodium selenite 5 x 10-mol Example 3 Preparation of beef kidney acetone powder> Immediately after stratification, cow kidney was treated in the same manner as in Example 1, and 350 g of coarsely ground organ pieces were obtained. Beef organ acetone powder was obtained in the same manner as in Example 1 except that the ground product was washed with 5200 g of cold acetone using 3300 g of cold acetone and 3400 g of cold water.
く抽出液の調製〉
液体基礎培地RPM11640とノ\ムF12とDMI
EMとを体積比で3:1:1となる割合で混合して得ら
れる混合液450−を、上記アセトン粉末90gに加え
て37℃で約40分間撹拌し、得られる懸濁液を300
゜rpmで約30分間遠心分離処理して上澄み液を得、
これを肌22遮フィルターで濾過し滅菌して抽出液を調
製した。これを「抽出液■」という。この抽出液■のタ
ンパク質濃度を実施例1と同様の方法で測定したところ
、13.7 mg / mf!であった。Preparation of extract> Liquid basal medium RPM11640, Nome F12 and DMI
EM and EM at a volume ratio of 3:1:1 was added to 90 g of the acetone powder and stirred for about 40 minutes at 37°C.
Centrifuge at °rpm for about 30 minutes to obtain a supernatant.
This was filtered through a skin 22 filter and sterilized to prepare an extract. This is called "extract liquid ■." When the protein concentration of this extract (■) was measured in the same manner as in Example 1, it was found to be 13.7 mg/mf! Met.
く培地の調製〉
粉末基礎培地RPMi1640 ノ30.6gと/%ム
F12+7)10、6 gとOIAEMの9.5gとを
混合し、この混合物を4,61の超純水に溶解させ、こ
れにL−グルタミン酸1゜5gと、炭酸水素ナトリウム
5.0gとを添加して溶解し、INの塩化す) IJウ
ム水溶液によりpH7,3に調整し、更に超純水を添加
して全量を5.Olとした後、濾過し滅菌して基礎培地
を得た。この基礎培地に、以下の物質を添加して動物細
胞培養用培地を調製した。Preparation of culture medium> Mix 30.6 g of powdered basal medium RPMi1640, 10.6 g of powdered basal medium RPMi1640 and 9.5 g of OIAEM, dissolve this mixture in ultrapure water of 4.61, and add to this. Add and dissolve 1.5 g of L-glutamic acid and 5.0 g of sodium bicarbonate, adjust the pH to 7.3 with an aqueous IJ solution, and further add ultrapure water to bring the total amount to 5.0 g. After making it into Ol, it was filtered and sterilized to obtain a basal medium. The following substances were added to this basal medium to prepare an animal cell culture medium.
抽出液(III) 9 mj!
リポタンパク質溶液A 16.4 dトラ
ンスフェリン 43 mgインスリン
63 mgエタノールアミン
110 mg2−メルカプトエタノ
ール 6X10−@モル亜セレン酸ナトリウム
6X10−”モルフェツイン 7
2 mg実施例4
〈抽出液の調製〉
実施例1において豚腎臓アセトン粉末の代わりに豚胃懺
アセトン粉末rK3875」(米国ングマ社製) 1
50gを用い、ltPM(1640と)\ムF12の混
合液の代りにリン酸緩衝液600m1を加えた以外は実
施例1と同様の方法で抽出液を得た。これを「抽出液■
」という。この抽出液■のタンパク質濃度を実施例1と
同様の方法で測定したところ、17mg/mであった。Extract (III) 9 mj!
Lipoprotein Solution A 16.4 dTransferrin 43 mg Insulin 63 mg Ethanolamine 110 mg 2-Mercaptoethanol 6X10-@mol Sodium Selenite
6X10-”Morphetwin 7
2 mg Example 4 <Preparation of extract> In Example 1, instead of pig kidney acetone powder, porcine stomach acetone powder rK3875' (manufactured by Nguma, USA) 1
An extract was obtained in the same manner as in Example 1, except that 50 g of ltPM(1640 and )\muF12 were used and 600 ml of phosphate buffer was added instead of the mixed solution of ltPM(1640 and )\muF12. This is called “extract liquid■
”. The protein concentration of this extract (2) was measured in the same manner as in Example 1 and was found to be 17 mg/m.
〈培地の調製〉
実施例3において抽出液I[[9mfの代わりに抽出液
IV7.3dを用いた以外は実施例3と同様にして動物
細胞培養用培地を調製した。<Preparation of medium> A medium for animal cell culture was prepared in the same manner as in Example 3 except that extract IV7.3d was used instead of extract I[[9mf.
実施例5
く培地の調製〉
実施例3において抽出液■の添加量を23.6ml!と
じた以外は実施例3と同様にして動物細胞培養用培地を
調製した。Example 5 Preparation of culture medium> In Example 3, the amount of extract liquid ■ added was 23.6 ml! An animal cell culture medium was prepared in the same manner as in Example 3, except for binding.
実施例6
〈培地の調製〉
実施例3において抽出液■の添加量を20.7ml!と
じ、リポタンパク質溶液Aの添加量を22.7rnlと
した以外は実施例3と同様にして動物細胞培養用培地を
調製した。Example 6 <Preparation of medium> In Example 3, the amount of extract ■ added was 20.7 ml! An animal cell culture medium was prepared in the same manner as in Example 3, except that the amount of lipoprotein solution A added was 22.7 rnl.
実験例
培養試験1
マウス骨髄腫(ミエローマ)由来の樹立細胞株である5
P210細胞、N5−1細胞、Ba1b/ C7ウスの
膵臓細胞とN5−1細胞とのハイブリドーマおよび黒色
種由来の80WES細胞を培養細胞として使用し、実施
例1〜6で調製した動物細胞培養用培地を用い、以下の
手順に従って培養試験を行った。Experimental Example Culture Test 1 Established cell line derived from mouse myeloma 5
Animal cell culture medium prepared in Examples 1 to 6 using P210 cells, N5-1 cells, a hybridoma of Ba1b/C7 mouse pancreatic cells and N5-1 cells, and 80WES cells derived from the black variety as cultured cells. A culture test was conducted using the following procedure.
細胞培養用24穴マルチウエルの各ウェルに予め実施例
1〜6で調製した動物細胞培養用培地を各々1miづつ
入れて温度37℃、5%炭酸ガス雰囲気下で平衡化させ
ておき、各ウェルに上記細胞をそれぞれlXl0’個の
割合で播種したものを細胞1種につき6組作り、温度3
7℃、5%炭酸ガス雰囲気下において培養した。培養を
開始してから3日目と5日目に細胞数をコールタ−カウ
ンターで計測し、同一条件の3つのウェルの細胞数の平
均イ直を求めた。1 micrometer of the animal cell culture medium prepared in Examples 1 to 6 was placed in each well of a 24-well multi-well for cell culture, and equilibrated at a temperature of 37°C under a 5% carbon dioxide atmosphere. The above cells were seeded at a ratio of lXl0' each to make six sets per cell type, and the temperature was 3.
The cells were cultured at 7°C under a 5% carbon dioxide atmosphere. On the 3rd and 5th day after the start of culture, the number of cells was counted using a Coulter counter, and the average number of cells in three wells under the same conditions was determined.
また対照培地として、以下の4種類の培地を用いて同様
の培養試験を行った。In addition, similar culture tests were conducted using the following four types of media as control media.
対照培地1 : RPMI 1640
対照培地2 :3RDF (基礎培地RPM11640
、I]旺およびハムF12を3:1:1の割合で
混合した培地)
対照培地3 : RPM11640に0.3容量%牛脂
児血清を添加したもの
対照培地4:3RDFに0.3容量%牛脂児血清を添加
したもの
なお、対照培地3および4のタンパク質濃度は、抽出液
■とほぼ同じである。Control medium 1: RPMI 1640 Control medium 2: 3RDF (basal medium RPM11640
, I]Medium containing 3:1:1 mixture of RDF and Ham's F12) Control medium 3: RPM11640 with 0.3% by volume beef fat serum Control medium 4: 3RDF with 0.3% by volume beef tallow The protein concentrations of control mediums 3 and 4 to which infant serum was added are approximately the same as those of extract solution ①.
結果を第1表〜第4表に示す。The results are shown in Tables 1 to 4.
第2表
(NS−1細胞培養試験)
第1表
(SP210細胞培養試験)
第3表
(ハイブリドーマ培養試験)
第4表
(BOWES細胞培養試験)
も原料とされるものが肝臓および/または腎臓であるた
め安価でかつ安定的な供給を確保することができ、従っ
て動物細胞を利用してモノクローナル抗体や有用生理活
性物質を工業的に生産する場合における浮遊系および接
着依存性のいずれの動物細胞の培養にも有利に使用する
ことができる。Table 2 (NS-1 cell culture test) Table 1 (SP210 cell culture test) Table 3 (Hybridoma culture test) Table 4 (BOWES cell culture test) The raw materials are also liver and/or kidney. Therefore, when using animal cells to industrially produce monoclonal antibodies and useful physiologically active substances, it is possible to ensure a low-cost and stable supply of animal cells. It can also be advantageously used for culture.
Claims (2)
ることを特徴とする動物細胞培養用培地。(1) An animal cell culture medium characterized by containing an extracted component derived from liver and/or kidney.
記載の動物細胞培養用培地。(2) The animal cell culture medium according to claim 1, which contains lipoprotein derived from egg yolk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63187984A JPH0239882A (en) | 1988-07-29 | 1988-07-29 | Culture medium for animal cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63187984A JPH0239882A (en) | 1988-07-29 | 1988-07-29 | Culture medium for animal cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0239882A true JPH0239882A (en) | 1990-02-08 |
Family
ID=16215583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63187984A Pending JPH0239882A (en) | 1988-07-29 | 1988-07-29 | Culture medium for animal cell |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0239882A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999063058A1 (en) * | 1998-06-01 | 1999-12-09 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| CN106244419A (en) * | 2016-08-30 | 2016-12-21 | 福建贝迪药业有限公司 | A kind of Chinese herbal medicine associating yolk antibody extracts byproduct fermentation and prepares production system and the technique of microbial ecological agent |
-
1988
- 1988-07-29 JP JP63187984A patent/JPH0239882A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999063058A1 (en) * | 1998-06-01 | 1999-12-09 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| EP1085083A4 (en) * | 1998-06-01 | 2002-11-27 | Chugai Pharmaceutical Co Ltd | CULTURE MEDIUM FOR CULTURE OF ANIMAL CELLS AND PROCESS FOR PRODUCING PROTEINS USING THE SAME |
| US6537782B1 (en) * | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| US6962812B2 (en) | 1998-06-01 | 2005-11-08 | Chugai Seiyaku Kabushiki Kaisha | Culture medium for culture of animal cell and method for producing protein using same |
| CN106244419A (en) * | 2016-08-30 | 2016-12-21 | 福建贝迪药业有限公司 | A kind of Chinese herbal medicine associating yolk antibody extracts byproduct fermentation and prepares production system and the technique of microbial ecological agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7270829B2 (en) | Industrial production of meat using cell culture methods | |
| Hauschka et al. | Vitamin D dependence of a calcium-binding protein containing gamma-carboxyglutamic acid in chicken bone. | |
| RU2604190C2 (en) | Method of low-ash poultry plasma protein powder production using poultry blood | |
| CA2990514A1 (en) | Process for the preparation of an additivie as a food supplement based on seaweeds for birds and animals; as well as the product obtained and its use in the food conversion and inthe production of bird and animal meat | |
| CN102242093A (en) | Comprehensive development method of high value-added active components of eggs | |
| NO161413B (en) | ANIMAL PRESENCE THAT INCLUDES INCOMPLETE NUTRITIONAL SUBSTANCES. | |
| JP7760610B2 (en) | Cell growth media for cultured meat production | |
| KR20230077644A (en) | Method for producing cultured meat using FBS(fetal bovine serum) substitute derived from slaughter by-products | |
| JPH0239882A (en) | Culture medium for animal cell | |
| US20250002859A1 (en) | Method for producing cultured meat by utilizing fbs substitute derived from butchery by-products | |
| RU2726615C1 (en) | Method for recovering proteins from bone marrow of animals | |
| Carroll et al. | Alanine uptake by isolated zooxanthellae of the mangrove jellyfish, Cassiopea xamachana. II. Inhibition by host homogenate fraction | |
| JPS60163888A (en) | Production of lipid component | |
| RU2298939C2 (en) | Method for protein isolation from marrow cells | |
| RU2808575C1 (en) | Method of immunoprophylaxis in poultry | |
| KR102827999B1 (en) | Composition for promoting cell growth derived from embryonated eggs for producing cultured meat and method for preparing the same | |
| Smith | A maintenance medium for tissue culture virus studies | |
| White | The Optimization of Tissue Culture Conditions for the Production of Cultivated Meat | |
| RU2553334C2 (en) | Method of extracting proteins from bone marrow cells | |
| EP0115284A2 (en) | Tissue culture medium | |
| RU2644248C2 (en) | Dense nutrient medium for cultivation and growing of tularemic microbe | |
| RU2236457C2 (en) | Method for preparing nutrient medium "limfokar" for culturing human and animal peripheral blood lymphocytes | |
| CN109924386B (en) | Biological compound preservative, preparation method thereof and application thereof in sturgeon caviar | |
| JPS61209585A (en) | Medium for cell culture | |
| Doherty | Murine metapodophalangeal sesamoid bone mineralization: a light and electron microscopy study |